ShortedShorted

NEUREN PHARMACEUT. ORDINARY (NEU) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
positive
1m ago

NEU (ASX:NEU) DAYBUE Royalties Lift Growth as Sales Rise

Highlights NEU (ASX:NEU) reports around growth in net sales and royalty income, driven by DAYBUE traction. Commercial partner expansion continues to support Rett syndrome treatment uptake. Market attention builds around biotech earnings visibility within the [ASX 200] healthcare sector. NEU (ASX:NEU) continues to grow royalty income from DAYBUE, with rising sales reinforcing its position as a key biotech name in the ASX healthcare sector. Australian healthcare stocks continue to attract...

Continue reading
Kalkine
neutral
1m ago

Why Is ASX:NEU Waiting on Europe Daybue Decision Shock?

Highlights Neuren Pharmaceuticals (ASX:NEU) is in focus as its partner awaits a key European regulatory decision on Daybue. Strong North American uptake of the therapy continues to underpin royalty-linked revenue expectations. The outcome could reshape the commercial pathway for Rett syndrome treatment expansion. Neuren Pharmaceuticals is in focus as a European decision on Daybue approaches, with North American success underpinning its rare disease growth narrative and global expansion ...

Continue reading